iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Short answer: An Indian clinical research provider does not automatically escape GST because its customer is incorporated or located overseas. The service may qualify as a zero-rated export only when every condition in section 2(6) of the Integrated Goods and Services Tax Act, 2017 (IGST Act) is met. The decisive issues are the supplier and recipient establishments, the contractual service actually supplied, the statutory place-of-supply rule, receipt of consideration in the permitted manner, and whether the parties are merely establishments of a distinct person.
Clinical trial coordination, monitoring, data analysis, laboratory testing, work on client-supplied samples, participant-facing procedures and payments made to Indian research institutions can produce different GST questions. Treating all of them as one generic clinical-research service is risky. This guide explains the framework applicable in India as of 13 October 2026 and shows how to analyse a particular engagement without assuming that an overseas invoice is automatically GST-free.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Designing Clinical Research | $102.98 | Buy on Amazon |
| 2 |
|
Clinical Research Exam Prep: MCQs and Scenarios for ACRP, SoCRA, and GCP (Clinical Research... | $10.90 | Buy on Amazon |
| 3 |
|
The Oxford Textbook of Clinical Research Ethics | $90.99 | Buy on Amazon |
| 4 |
|
Designing Clinical Research | $48.56 | Buy on Amazon |
| 5 |
|
Principles and Practice of Clinical Research | $120.77 | Buy on Amazon |
What determines GST on an overseas clinical-research contract?
Export status is a cumulative legal test, not a payment or invoicing label. Section 2(6) of the IGST Act requires all five conditions below:
| Condition | What to verify in a clinical-research engagement |
|---|---|
| Supplier located in India | Identify the Indian GST-registered location and the establishment that actually performs and invoices the work. |
| Recipient located outside India | Identify the legal customer and the establishment that receives the service. A foreign parent, branch or affiliate may raise a distinct-establishment issue. |
| Place of supply outside India | Apply section 13, including its special rules. The recipient-location default can be displaced by a goods-availability or individual-presence rule. |
| Consideration received as required by law | Confirm receipt in convertible foreign exchange or in Indian rupees where the Reserve Bank of India permits that mode, and retain evidence of receipt. |
| Supplier and recipient are not merely establishments of a distinct person | Check whether the parties are separate legal persons for this test or establishments of the same person treated as distinct under the IGST Act. |
Failure of any one condition means the supply is not an export under section 2(6), even if the customer is abroad and the invoice is settled in US dollars, euros or another foreign currency. The resulting GST treatment must then be determined under the applicable domestic supply rules and the actual locations of the supplier and place of supply.
#1 Best Overall
How the place-of-supply rules work
The general recipient-location rule
Section 13 applies when the supplier or recipient is outside India. Its section 13(2) rule states: "The place of supply of services except the services specified in sub-sections (3) to (13) shall be the location of the recipient of services." For a straightforward cross-border service supplied to a foreign customer, this generally places the supply outside India and can satisfy the third export condition.
The wording is deliberately qualified. Sub-sections 13(3) to 13(13) contain exceptions, so a provider must first test whether a special rule describes the work. A contract should not be classified solely by its title, such as CRO services, clinical trial services or research support.
Services involving goods made physically available
Section 13(3)(a) addresses services supplied in respect of goods that the recipient must make physically available to the supplier or to a person acting for the supplier. In a clinical programme, the relevant items could include medicines, reference products, biological samples, reagents, devices or other materials supplied by the overseas customer.
Free tools Windows power users keep installed
One-click scans. No signup required.
Physical shipment alone does not answer the question. Document what the item is, why it is needed, whether the supplier takes possession or control, what work is performed on it, and what happens after the work. Ask whether the service is principally testing or processing that item, or whether the item is incidental to a broader coordination, monitoring or analytical deliverable. Section 13(3)(a) also contains provisos, including a temporary-import-and-re-export treatment or process exception whose conditions must be checked against the actual movement and return of the goods.
Services requiring an individual’s physical presence
Section 13(3)(b) covers services supplied to an individual that require that individual, or the individual’s representative, to be physically present with the supplier. Participant-facing clinical procedures can require a separate analysis from remote trial management or data work. Identify who the legal recipient is, whether the service is supplied to that individual or to a sponsor, and whether physical presence is legally and operationally necessary for the particular deliverable.
A participant visiting an Indian site does not, by itself, establish every fact needed for section 13(3)(b). The contract, recipient identity and nature of the service must be read together. Where a special rule applies, the recipient-location default in section 13(2) cannot be used to reach an export conclusion.
Classify the actual clinical-research deliverables
Separate the scope before deciding GST. A single master services agreement may contain several deliverables with different place-of-supply risks.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
| Deliverable or activity | Questions that affect GST analysis | Initial issue to test |
|---|---|---|
| Trial design, protocol support and project management | Who receives the advice and outputs? Is the work performed through Indian personnel for a foreign establishment? | Section 13(2) is the starting point unless another exception applies. |
| Site selection, investigator coordination and monitoring | Are these coordination and oversight services, or are they services supplied directly to participants or in respect of goods? | Separate the sponsor-facing coordination from any participant-facing or goods-related work. |
| Laboratory testing and sample analysis | Who supplies the samples, are they physically made available, and is testing the contracted service? | Examine section 13(3)(a), including any applicable proviso. |
| Bioequivalence or bioavailability studies | What reference materials, samples or medicines are supplied, and what processing or testing is performed in India? | Map each material to the service and the statutory goods-availability test. |
| Data management and statistical analysis | Are the outputs analytical services delivered to the foreign recipient without a special physical-performance rule? | Usually begin with section 13(2), then test all exceptions. |
| Participant-facing procedures | Who is the recipient and does the work require the person or representative to be present with the supplier? | Consider section 13(3)(b) and document the recipient relationship. |
| Amounts paid onward to Indian institutions | Is the provider acting for its own account or seeking exclusion as a pure agent under the valuation rules? | Analyse the contractual and payment arrangement separately; an overseas payer does not automatically make onward amounts pure-agent reimbursements. |
If the agreement bundles these activities, create a deliverables schedule and allocate fees where commercially and operationally justified. A vague description such as clinical research support can make it difficult to establish which place-of-supply rule applied to each charge.
Rank #3
When can the supply be zero-rated?
When all section 2(6) conditions are met, the service is an export of services and is zero-rated under the IGST framework. Zero-rating is not the same as an exemption: eligible input tax credit and refund mechanisms can remain available, subject to statutory and procedural conditions.
Export under a letter of undertaking or bond
CBIC describes a route under which an eligible exporter supplies without payment of IGST against a letter of undertaking or bond and claims a refund of eligible unutilised input tax credit. The provider must follow the current filing, undertaking, return and refund requirements applicable to its status and transaction period.
Export on payment of IGST
CBIC also describes a route in which the exporter pays IGST and subsequently claims a refund, subject to the applicable law and procedure. Do not select a route merely because it was used on an earlier contract; check current electronic filing requirements, matching or reporting conditions, and the provider’s ability to evidence export receipt.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →In either route, preserve the contract, purchase orders, invoices, work orders, milestone acceptance, foreign-customer details, bank or authorised-dealer records showing receipt, GST returns, LUT or bond documentation where relevant, and evidence supporting the place-of-supply analysis. A refund claim cannot cure a failure to meet the substantive export conditions.
Rank #4
A practical decision process for a new engagement
- Identify the supplier establishment. Record the Indian GSTIN, state, fixed establishment or branch involved, personnel performing the work and the entity issuing the invoice.
- Identify the recipient. Name the contracting legal entity and the establishment receiving the benefit. Check whether the foreign customer and Indian provider are separate persons or establishments of a distinct person.
- Break down the scope. List design, coordination, monitoring, testing, laboratory, data, participant-facing and reimbursable activities as separate deliverables.
- Inventory physical materials. Record medicines, samples, reagents, devices and equipment supplied by the customer, their ownership, transport, custody, use, destruction or return, and whether they are essential to the service.
- Test section 13. Start with section 13(2), then examine section 13(3)(a), section 13(3)(b) and any other relevant subsection or proviso. Write a short conclusion for each deliverable, not one conclusion for the whole contract by assumption.
- Verify consideration. Confirm when and how payment is received, whether the currency or permitted Indian-rupee route satisfies the statute, and whether bank evidence ties the receipt to the exported service.
- Check zero-rating procedure. If the five export conditions are satisfied, choose the applicable LUT/bond or IGST-refund route after checking current rules, forms, deadlines and return reporting.
- Retain an audit file. Keep the signed contract, scope matrix, correspondence about samples and participants, site records, invoices, receipts, tax returns and the written place-of-supply reasoning.
How the official clinical-research rulings should be used
Advance rulings are fact-specific. The records below are useful for identifying questions, but they do not establish a universal result for every CRO or clinical-trial contract.
| Record | What it addresses | Safe way to use it |
|---|---|---|
| Cliantha Research Limited, Maharashtra, GST-ARA-119/2018-19/B-50, Mumbai, 4 May 2019 | The applicant asked whether proposed clinical research services to entities outside India were export services under section 2(6) or liable to GST. | Read the complete order, including facts and operative conclusion, before relying on it. The issue listing alone does not establish the holding. |
| Asiatic Clinical Research Private Limited, Karnataka, KAR/AAR/80/2019-20, 24 September 2019 | The listed questions include export treatment for services to a foreign client and whether amounts collected and paid onward to local research institutions were received as a pure agent. | Do not infer either answer from the issue description. The contractual payment and agency facts must be compared with the proposed engagement. |
| Parexel International Clinical Research, Karnataka, 2019 | The order concerns clinical-trial coordination and monitoring in India and discusses place-of-supply provisions, including section 13(3). | Consult the full order and its factual findings before stating or applying its conclusion. |
| GST Council 37th-meeting agenda material | Historical discussion of pharmaceutical R&D, processing and testing, bioequivalence and bioavailability studies, clinical trials, and client-supplied reference materials or samples. | Use it for issue spotting only. An agenda analysis or proposal is not enacted law or a binding ruling. |
Common mistakes and how to correct them
Mistake: treating a foreign invoice as proof of export
Correction: Prepare a section 2(6) checklist and attach a place-of-supply memorandum. The customer’s address and currency are evidence, not conclusive proof.
Mistake: analysing the contract label instead of the work
Correction: Match each invoice line to the actual deliverable, personnel, location, materials and recipient. Re-document the analysis when a protocol amendment changes the work.
Mistake: ignoring client-supplied samples
Correction: Record custody and purpose for every sample or product. Determine whether the service is in respect of goods made physically available and assess any temporary-import-and-re-export proviso.
Best Value
- Excellent clinical research resource!
Mistake: assuming all participant activity has the same treatment as sponsor reporting
Correction: Identify the recipient and test whether an individual’s physical presence is required for the particular service. Keep participant-facing operations distinct from remote data or coordination work.
Mistake: treating onward payments as automatically excluded reimbursements
Correction: Analyse the pure-agent question independently, using the agreement, authorisations, invoices, payment trail and valuation rules. A pass-through label is not enough.
Mistake: relying on a 2019 ruling without checking current law
Correction: Read the operative text and facts, then check amendments, notifications and current procedural rules before using an advance ruling in a 2026 transaction.
Recommended Free Tools
Illustrative outcomes
Example 1: sponsor-facing data and monitoring service
An Indian provider designs a protocol, monitors Indian sites and delivers data analysis to a separate overseas sponsor. The sponsor supplies no material that must be made physically available for the contracted work, and the deliverables are accepted by the foreign establishment. The provider would begin with section 13(2), then verify all five section 2(6) conditions and payment evidence. The result is not automatic, but this fact pattern is materially different from a contract whose main deliverable is testing a customer-supplied product.
Example 2: laboratory testing of imported samples
A foreign client sends samples to India and the Indian laboratory’s principal obligation is to test those samples and report results. The provider should document custody, the purpose of the samples and their return, destruction or retention. Section 13(3)(a), including its provisos, must be examined before relying on section 13(2). The invoice being paid from abroad does not resolve that statutory question.
Example 3: participant-facing procedure
An Indian site performs a procedure requiring a participant to attend in person, while a foreign sponsor funds the study. The analysis must identify whether the service is supplied to the sponsor, the individual or another recipient under the contract and whether section 13(3)(b) applies. Do not classify the entire study from the sponsor’s overseas address alone.
What to confirm before filing or issuing an invoice
- The legal names, GST registrations and establishments of both parties are correct.
- The scope and invoice lines describe actual services rather than an unexplained bundle.
- Any samples, medicines, devices or other goods supplied by the customer are documented with their role and disposition.
- Participant-presence requirements and the recipient of participant-facing work are recorded.
- Foreign-exchange or permitted-rupee receipt evidence is available and reconciled to invoices.
- The provider has tested distinct-person status and any intercompany arrangement.
- The chosen LUT/bond or IGST-refund route matches current rules and return reporting.
- Any reliance on an advance ruling is limited to comparable facts and supported by the full operative order.
Because the tax result turns on contract wording and actual performance, a provider should obtain transaction-specific advice from an Indian GST professional experienced with export-of-services and clinical-research arrangements before finalising a position, especially where samples, participant services, branches or reimbursements are involved.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsQuick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
